Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus
Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822. Online ahead of print.ABSTRACTInfluenza therapeutics with new targets and modes of action are urgently needed due to the frequent emergence of mutants resistant to currently available anti-influenza drugs. Here we report the in vitro and in vivo anti-influenza A virus activities of cyperenoic acid, a natural compound, which was isolated from a Chinese medicine Croton crassifolius Geise. Cyperenoic acid could potently suppress H1N1, H3N2 and H9N2 virus replication with IC50 values ranging from 0.12 to 15.13 μM, and showed a low cytotoxicity against MD...
Source: Antiviral Research - February 13, 2024 Category: Virology Authors: Xiaoli Zhang Yiping Xia Peibo Li Zhongnan Wu Ruilin Li Jialiao Cai Yubo Zhang Guocai Wang Yaolan Li Wei Tang Weiwei Su Source Type: research
Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses
Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823. Online ahead of print.ABSTRACTMucosal immunity has regained its spotlight amidst the ongoing Coronavirus Disease 19 (COVID-19) pandemic, with numerous studies highlighting the crucial role of mucosal secretory IgA (SIgA) in protection against SARS-CoV-2 infections. The observed limitations in the efficacy of currently authorized COVID-19 vaccines in inducing effective mucosal immune responses remind us of the limitations of systemic vaccination in promoting protective mucosal immunity. This resurgence of interest has motivated the development of vaccin...
Source: Antiviral Research - February 8, 2024 Category: Virology Authors: Divya Sinha Melyssa Yaugel-Novoa Louis Waeckel St éphane Paul St éphanie Longet Source Type: research
Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition
Antiviral Res. 2024 Feb 5;223:105833. doi: 10.1016/j.antiviral.2024.105833. Online ahead of print.ABSTRACTThe Hepatitis B Virus (HBV) ribonuclease H (RNase H) although promising remains an unexploited therapeutic target. HBV RNase H inhibition causes premature termination of viral minus-polarity DNA strands, prevents the synthesis of the viral positive-polarity DNA strand, and causes accumulation of RNA:DNA heteroduplexes within viral capsids. As part of our ongoing research to develop more potent anti-HBV RNase H inhibitors, we designed, synthesized and analyzed a library of 18 novel compounds (17 N-hydroyxpyridinedione (...
Source: Antiviral Research - February 7, 2024 Category: Virology Authors: Erofili Giannakopoulou Vasiliki Pardali Tiffany C Edwards Molly Woodson Razia Tajwar John E Tavis Grigoris Zoidis Source Type: research
An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses
In this study, we developed a recombinant adenovirus vaccine, AD5-N, based on the nucleocapsid(N) protein of FCoV. The immunogenicity of AD5-N was evaluated through intramuscular immunization in 6-week-old Balb/c mice and 9-12 months old cats. Compared to the control group, AD5-N specifically induced a significant increase in IgG and SIgA levels in the vaccinated mice. Furthermore, AD5-N not only effectively promoted strong cellular immune responses in cats but also induced high levels of specific SIgA, effectively helping cats resist FCoV infection. Our findings suggest that adenovirus vector vaccines based on the N gene ...
Source: Antiviral Research - February 4, 2024 Category: Virology Authors: Yuanhong Wang Yun Liu Junna Wang Miao Zhang Xiaoying Deng Junhan Song Jie Zhu Lingxue Yu Guoxin Li Guangqing Liu Source Type: research
Miltefosine reduces coxsackievirus B3 lethality of mice with enhanced STAT3 activation
This study was therefore designated to test the antiviral effects of miltefosine against CVB3 in vitro and especially, in mice, as few studies test miltefosine in vitro, but not in vivo. In vitro results showed that miltefosine inhibited viral replication with enhanced activation of the cellular transcription factor, STAT3, which is reported to reduce CVB3 both in vitro and in mice. Notably, STAT3 knockdown abolished the anti-CVB3 activity of miltefosine in vitro. Mouse studies demonstrated that miltefosine pretreatment reduced CVB3 lethality of mice with decreased virus loads, organ damage, and apoptosis, but enhanced STA...
Source: Antiviral Research - February 3, 2024 Category: Virology Authors: Chun Yu Zhang Cheng-Huei Hung Yi-Ling Hsiao Tung-Miao Chang Yu-Chieh Su Li-Chiu Wang Shih-Min Wang Shun-Hua Chen Source Type: research
Therapeutic antibodies and alternative formats against SARS-CoV-2
Antiviral Res. 2024 Feb 1;223:105820. doi: 10.1016/j.antiviral.2024.105820. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines and therapeutics to confront infection, the virus remains a threat. The ancestor viral strain has evolved into several variants of concern, with the Omicron variant now having many distinct sublineages. Consequently, most available antibodies targeting the spike went obsolete and thus new therapies or therapeutic formats are needed. In this review we foc...
Source: Antiviral Research - February 2, 2024 Category: Virology Authors: Rahel R Winiger Laurent Perez Source Type: research
Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors
This study contributes to the understanding of the molecular mechanisms of cCMV neuropathogenesis and paves the way for further consideration of anti-HCMV drugs as candidate therapeutic agents for the amelioration of cCMV-associated neurological manifestations.PMID:38286212 | DOI:10.1016/j.antiviral.2024.105816 (Source: Antiviral Research)
Source: Antiviral Research - January 29, 2024 Category: Virology Authors: Marta Trevisan Anna Pianezzola Marco Onorati Lorenzo Apolloni Mauro Pistello Ravit Arav-Boger Giorgio Pal ù Beatrice Mercorelli Arianna Loregian Source Type: research
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results
Antiviral Res. 2024 Feb;222:105818. doi: 10.1016/j.antiviral.2024.105818. Epub 2024 Jan 25.ABSTRACTIn this research, we employed a deep reinforcement learning (RL)-based molecule design platform to generate a diverse set of compounds targeting the neuraminidase (NA) of influenza A and B viruses. A total of 60,291 compounds were generated, of which 86.5 % displayed superior physicochemical properties compared to oseltamivir. After narrowing down the selection through computational filters, nine compounds with non-sialic acid-like structures were selected for in vitro experiments. We identified two compounds, DS-22-inf-009 a...
Source: Antiviral Research - January 27, 2024 Category: Virology Authors: Roza Izmailyan Mher Matevosyan Hamlet Khachatryan Anastasiya Shavina Smbat Gevorgyan Artur Ghazaryan Irina Tirosyan Yeva Gabrielyan Marusya Ayvazyan Boris Martirosyan Vardan Harutyunyan Hovakim Zakaryan Source Type: research
Antiviral effect of peptoids on hepatitis B virus infection in cell culture
In conclusion, the peptoid TM19 was identified as a potent inhibitor of HBV. This peptoid prevents HBV infection by disrupting viral particles and is a candidate for a new class of anti-HBV reagents.PMID:38272318 | DOI:10.1016/j.antiviral.2024.105821 (Source: Antiviral Research)
Source: Antiviral Research - January 25, 2024 Category: Virology Authors: Asako Murayama Hitomi Igarashi Norie Yamada Hussein Hassan Aly Natalia Molchanova Jennifer S Lin Hironori Nishitsuji Kunitada Shimotohno Masamichi Muramatsu Annelise E Barron Takanobu Kato Source Type: research
A lipid index for risk of hyperlipidemia caused by anti-retroviral drugs
In this study, we propose a pharmacological lipid index to estimate the risk of hyperlipidemia caused by anti-retroviral drugs. Lipid droplets were stained in cells treated with anti-retroviral drugs and cyclosporin A. Signal intensities of lipid droplets were plotted against the drug concentrations to obtain an isodose of 10 μM of cyclosporin A, which we call the Pharmacological Lipid Index (PLI). The PLI was then normalized by EC50. PLI/EC50 values were low in early proteinase inhibitors and the nucleoside reverse transcriptase inhibitor, d4T, indicating high risk of hyperlipidemia, which is consistent with previous fin...
Source: Antiviral Research - January 25, 2024 Category: Virology Authors: Mari Shimura Nobuyo Higashi-Kuwata Asuka Fujiwara Mai Taniguchi Takayuki Ichinose Fumie Hamano Masaaki Uematsu Takato Inoue Satoshi Matsuyama Takahiro Suzuki Arun K Ghosh Hideo Shindou Takao Shimuzu Hiroaki Mitsuya Source Type: research
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome
Antiviral Res. 2024 Jan 24;223:105813. doi: 10.1016/j.antiviral.2024.105813. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has heavily challenged the global healthcare system. Despite the vaccination programs, the new virus variants are circulating. Further research is required for understanding of the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and for discovery of therapeutic agents against the virus. Here, we took advantage of drug repurposing to identify if existing drugs could inhibit SARS-CoV-2 infection. We established an open high throughput pla...
Source: Antiviral Research - January 25, 2024 Category: Virology Authors: Mariia S Bogacheva Suvi Kuivanen Swapnil Potdar Antti Hassinen Sini Huuskonen Ina P öhner Tamara J Luck Laura Turunen Michaela Feodoroff Leonora Szirovicza Kirsi Savijoki Jani Saarela P äivi Tammela Lassi Paavolainen Antti Poso Markku Varjosalo Olli Kal Source Type: research
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains
Antiviral Res. 2024 Feb;222:105814. doi: 10.1016/j.antiviral.2024.105814. Epub 2024 Jan 24.ABSTRACTSince the start of the SARS-CoV-2 pandemic, the search for antiviral therapies has been at the forefront of medical research. To date, the 3CLpro inhibitor nirmatrelvir (Paxlovid®) has shown the best results in clinical trials and the greatest robustness against variants. A second SARS-CoV-2 protease inhibitor, ensitrelvir (Xocova®), has been developed. Ensitrelvir, currently in Phase 3, was approved in Japan under the emergency regulatory approval procedure in November 2022, and is available since March 31, 2023. One of th...
Source: Antiviral Research - January 25, 2024 Category: Virology Authors: Hawa Sophia Bouzidi Jean-S élim Driouich Rapha ëlle Klitting Orn éllie Bernadin G éraldine Piorkowski Rayane Amaral Laurent Fraisse Charles E Mowbray Ivan Scandale Fanny Escudi é Eric Chatelain Xavier de Lamballerie Antoine Nougair ède Franck Touret Source Type: research
HAND2 suppresses favipiravir efficacy in treatment of Borna disease virus infection
This study provides novel insights into the molecular mechanisms underlying T-705 interference in some cell types and inspires the development of improved T-705 derivatives for the treatment of RNA viruses.PMID:38262560 | DOI:10.1016/j.antiviral.2024.105812 (Source: Antiviral Research)
Source: Antiviral Research - January 23, 2024 Category: Virology Authors: Da Teng Keiji Ueda Tomoyuki Honda Source Type: research
